- |||||||||| Review, Journal: Depression and Long-Term Prescription Opioid Use and Opioid Use Disorder: Implications for Pain Management in Cancer. (Pubmed Central) - Apr 30, 2022
Existing evidence is inadequate to definitively recommend methylphenidate or novel agents, such as ketamine or psilocybin, as adjunctive treatments for cancer-related depression and pain...Buprenorphine and methadone are indicated for the treatment of opioid use disorder, and while they have not been systematically studied for treatment of opioid use disorder in patients with cancer pain, they do provide analgesia for cancer pain. While an interdisciplinary team approach to manage psychological stress may be beneficial, this may not be possible for patients treated outside of comprehensive cancer centers.
- |||||||||| escitalopram / Generic mfg.
Trial completion date, Trial primary completion date: ELISA: Escitalopram and Language Intervention for Subacute Aphasia (clinicaltrials.gov) - Apr 29, 2022
P2, N=88, Recruiting,
While an interdisciplinary team approach to manage psychological stress may be beneficial, this may not be possible for patients treated outside of comprehensive cancer centers. Trial completion date: Jun 2026 --> Jan 2026 | Trial primary completion date: Jun 2026 --> Sep 2025
- |||||||||| escitalopram / Generic mfg.
Journal: One-week escitalopram intake alters the excitation-inhibition balance in the healthy female brain. (Pubmed Central) - Apr 28, 2022
Higher plasma escitalopram levels at a single dose were associated with better maintenance of these EIB changes throughout the drug administration week. These findings demonstrate the potential for 1/f slope to predict individual cortical responsivity to SSRIs and widen the lens through which we map the human brain by testing an interventional psychopharmacological design in a clearly defined endocrinological state.
- |||||||||| escitalopram / Generic mfg.
Journal: Cocaine increases stimulation-evoked serotonin efflux in the nucleus accumbens. (Pubmed Central) - Apr 27, 2022
N-FSCV's selective measurement of serotonin release in vivo was confirmed pharmacologically via administration of the selective serotonin reuptake inhibitor escitalopram (10 mg/kg ip) that effectively increased the signal in a separate group of rats (n = 5)...Selectivity to serotonin was further confirmed in vitro in which dopamine was minimally detected by N-FSCV with a serotonin to dopamine response ratio of 1:0.04 (200 nM of serotonin:1 mM dopamine ratio; p = 0.0048; n = 5 electrodes). This study demonstrates a noteworthy influence of cocaine on serotonin dynamics, and confirms that N-FSCV can effectively and selectively measure phasic serotonin release in the NAcc.
- |||||||||| escitalopram / Generic mfg.
Journal: Effective connectivity between resting-state networks in depression. (Pubmed Central) - Apr 27, 2022
A primary limitation of the current study was the small size; however, the group was carefully chosen, well-characterized, and included only medication-free patients. Further research in large samples of placebo-controlled studies would be required to confirm the results.
- |||||||||| aripiprazole / Generic mfg., escitalopram / Generic mfg.
Toward Precision Medicine in Psychiatry Using Pharmacogenomics (Rooms 283-285 , Ernest N. Morial Convention Center) - Apr 26, 2022 - Abstract #APA2022APA_284;
This presentation targets researchers, trainees and clinicians and will provide them with updates and state-of-the-art summaries of key concept and strategies of psychiatric PGx: 1) Review the evidence, clinical utility and publications including randomized clinical trials of distinct gene-drug pairs (e.g., CYP2C19 and escitalopram and CYP2D6 and aripiprazole); 2) discuss current expert recommendations (e.g., Clinical Pharmacogenomics Implementation Consortium) how applying PGx information in clinical practice 3) highlight ongoing implementation efforts in North-America and 4) provide feedback given by patients and physicians who chose to use PGx information and 5) provide a synopsis with practical guidelines for psychiatrists and clinicians. Time for discussion format will be provided to interact with the audience''s questions, experiences and concerns related to psychiatric pharmacogenetics.
- |||||||||| escitalopram / Generic mfg.
Journal: The Importance of Endoplasmic Reticulum Stress as a Novel Antidepressant Drug Target and Its Potential Impact on CNS Disorders. (Pubmed Central) - Apr 24, 2022
Among the tested antidepressants (escitalopram, amitriptyline, S-ketamine and R-ketamine), only S-ketamine, and to a lesser extent R-ketamine, induced the expression of most ER stress-responsive genes in astrocytes...Under normal conditions, S-ketamine played the key role in increasing the release of brain-derived neurotrophic factor (BDNF), indicating that the drug has a complex mechanism of action in astrocytes, which may contribute to its therapeutic effects. Our findings are the first to shed light on the relationship between old astrocyte specifically induced substance (OASIS) stabilized by ER stress and (R-)S-ketamine; however, the possible involvement of OASIS in the mechanism of therapeutic ketamine action requires further study.
- |||||||||| Nuplazid (pimavanserin) / Acadia Pharma
Review, Journal: Psychosis in Alzheimer disease - mechanisms, genetics and therapeutic opportunities. (Pubmed Central) - Apr 22, 2022
Current pharmacological and non-pharmacological treatment options are discussed, with a focus on safety and precision medicine. We also explore trial data for pimavanserin, a novel agent that shows promise for the treatment of psychosis in people with dementia, and discuss existing agents that might be useful but need further exploration such as escitalopram, lithium, cholinesterase inhibitors and vitamin D. Although the assessment and management of psychosis in people with dementia remain challenging, new opportunities are providing direction and hope to the field.
- |||||||||| escitalopram / Generic mfg.
Journal: Increased global integration in the brain after psilocybin therapy for depression. (Pubmed Central) - Apr 22, 2022
P2
The antidepressant response to escitalopram was milder and no changes in brain network organization were observed. Consistent efficacy-related brain changes, correlating with robust antidepressant effects across two studies, suggest an antidepressant mechanism for psilocybin therapy: global increases in brain network integration.
- |||||||||| sertraline / Generic mfg., fluoxetine / Generic mfg., escitalopram / Generic mfg.
Poster Tour: Mental Health (In-person) - Apr 21, 2022 - Abstract #ISPOR2022ISPOR_1916;
Further study is needed to assess the comparative effectiveness and health-care utilization of these medications. Posters featured in this tour: CO110: Comparative Effectiveness of Sertraline, Fluoxetine Vs Escitalopram Among Adults with Depression in the United States CO122: Patient Versus Caregiver and Clinician Reports of Cognitive Difficulties in Patients with Schizophrenia Switching to Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: A Post Hoc Analysis EE9: Real-World Naloxone Prescription Trends, Costs, and Comorbidities in Commercial, Managed Medicare, and Medicaid Patients in the United States (2016-2019) RWD66: Leveraging Laboratory Results from Multiple Data Sources to Re-Assess a Possible Association between Serum Uric Acid and Schizophrenia in Real World Practice Settings SA15: Real-World Calibration of the Disease Recovery Evaluation and Modification (DREaM) Randomized Clinical Trial in Adult Medicaid Beneficiaries With Recent-Onset Schizophrenia
- |||||||||| memantine / Generic mfg., escitalopram / Generic mfg.
Journal: Default mode network connectivity and treatment response in geriatric depression. (Pubmed Central) - Apr 21, 2022
P4
This relatively simple application based on clinical symptoms and function seems to be cost-effective method to identify individuals who are more likely to respond to antidepressant treatment. Increased within-network connectivity of core DMN nodes was more strongly correlated with depressive symptom improvement with ESC/MEM than with ESC/PBO, supporting an improved engagement of brain circuitry implicated in the amelioration of depressive symptoms with combined ESC/MEM treatment in older adults with depression and subjective memory complaints.
- |||||||||| agomelatine / Generic mfg., escitalopram / Generic mfg.
Journal: Beyond Response: Aiming for Quality Remission in Depression. (Pubmed Central) - Apr 21, 2022
Antidepressant therapy is only effective if patients continue to take their medication, and high rates of early discontinuation have been reported. Therefore, when selecting treatment for depression, physicians can maximize the likelihood of adherence and persistence by taking into account both the antidepressant efficacy of treatment, its adverse effects and acceptability to patients.
- |||||||||| mirtazapine / Generic mfg., escitalopram / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date: MIR-P: Mirtazapine in Cancer-related Poly-symptomatology (clinicaltrials.gov) - Apr 20, 2022
P3, N=418, Recruiting,
Therefore, when selecting treatment for depression, physicians can maximize the likelihood of adherence and persistence by taking into account both the antidepressant efficacy of treatment, its adverse effects and acceptability to patients. Not yet recruiting --> Recruiting | Trial completion date: May 2023 --> Feb 2024 | Trial primary completion date: May 2023 --> Feb 2024
- |||||||||| Journal, Adverse events: Sexual side effects from treatment with SSRI (Pubmed Central) - Apr 19, 2022
This review suggests management strategies including dose reduction, change of medication and add-on treatment. A small group of patients experience post-SSRI dysfunction, in which sexual dysfunction persists after treatment termination.
- |||||||||| escitalopram / Generic mfg.
Journal: Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression. (Pubmed Central) - Apr 19, 2022
P2
This 2-arm double-blind randomized controlled trial compared escitalopram with psychedelic-assisted therapy for moderate-severe depressive disorder (N = 59)...Therapeutic alliance ahead of the second session had a direct impact on final depression scores, not mediated by the acute experience, with a weaker alliance ahead of the second psilocybin session predicting higher absolute depression scores at endpoint (β = -0.49, p < 0.001) Future research could consider therapist training and characteristics; specific participant factors, e.g., attachment style or interpersonal trauma, which may underlie the quality of the therapeutic relationship, the psychedelic experience and clinical outcomes; and consider how therapeutic approaches might adapt in cases of weaker therapeutic alliance. Clinical Trial Registration: This trial is registered at http://clinicaltrials.gov, identifier (NCT03429075).
- |||||||||| sertraline / Generic mfg., escitalopram / Generic mfg.
Retrospective data, Journal: General antidepressants prescribing trends 2009-2018 in Slovenia: a cross-sectional retrospective database study. (Pubmed Central) - Apr 14, 2022
SSRIs (selective serotonin reuptake inhibitors) were the most prescribed antidepressants (70% share), with escitalopram and sertraline the most commonly prescribed antidepressants. The prevalence of antidepressant prescribing and antidepressant consumption is increasing, mainly due to the population ageing and the increasing prescribing in elderly patients.Key PointsThe prevalence of antidepressant prescribing as well as antidepressants' consumption is increasing, reflecting both population ageing and rising prescribing rates.The increase in prevalence and consumption is most dramatic in the oldest patients (over 80 years of age).SSRIs continue to be the most commonly prescribed antidepressants, whilst prescribing of SNRIs is increasing.Future research should focus on evaluating appropriate prescribing of antidepressants (treatment selection, dosage and duration), especially in the elderly.
- |||||||||| lorazepam / Generic mfg., escitalopram / Generic mfg.
Preclinical, Journal: Escitalopram and lorazepam differentially affect nesting and open field behaviour in deer mice exposed to an anxiogenic environment. (Pubmed Central) - Apr 13, 2022
We show that LNB behaviour in deer mice is stable, irrespective of the anxiety-related context in which it is assessed, and that LNB mice find an open field arena to be less aversive compared to NNB mice. Escitalopram and lorazepam differentially affect the nesting and open field behaviour of LNB expressing mice, confirming deer mouse LNB as a repetitive behavioural phenotype that is related to a compulsive-like process which is regulated by the serotonergic system.
- |||||||||| bupropion ER / Generic mfg., escitalopram / Generic mfg.
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: PRECISE-D: Promoting Enhanced Pharmacotherapy Choice Through Immunomarkers Evaluation in Depression (clinicaltrials.gov) - Apr 13, 2022
P4, N=18, Terminated,
Escitalopram and lorazepam differentially affect the nesting and open field behaviour of LNB expressing mice, confirming deer mouse LNB as a repetitive behavioural phenotype that is related to a compulsive-like process which is regulated by the serotonergic system. N=70 --> 18 | Trial completion date: Jun 2023 --> Mar 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2023 --> Mar 2022; terminated during COVID due to inability to see participants in person.
- |||||||||| escitalopram / Generic mfg.
Preclinical, Journal: Sustained escitalopram administration affects glucose metabolism in the rat brain. (Pubmed Central) - Apr 12, 2022
Therefore, repeated exposure to escitalopram alters the activity of several brain areas closely related to the serotonergic system, and previously identified as key regions in the antidepressant effect induced by SSRIs. Furthermore, some of the changes found, such as the dampened metabolism in the ventral tegmental area, are similar to changes that have been described after treating with other fast-acting antidepressant approaches.
- |||||||||| escitalopram / Generic mfg.
Enrollment open, Enrollment change, Trial completion date, Trial primary completion date: ELISA: Escitalopram and Language Intervention for Subacute Aphasia (clinicaltrials.gov) - Apr 12, 2022
P2, N=88, Recruiting,
Clinical Trial Registration number: GENDEP is registered at EudraCT2004-001723-38 (http://eudract.emea.europa.eu) and ISRCTN03693000 (www.controlled-trials.com). Completed --> Recruiting | N=61 --> 88 | Trial completion date: Apr 2022 --> Jun 2026 | Trial primary completion date: Apr 2022 --> Jun 2026
- |||||||||| rivaroxaban / Generic mfg.
Observational data, Retrospective data, Journal: Rivaroxaban and selective serotonin reuptake inhibitors: Bleeding risk resulting from their concomitant use. (Pubmed Central) - Apr 12, 2022
We observed a predictive role of CRP for remission and symptomatic improvement after escitalopram treatment of MDD patients based on continuous or categorical CRP levels. Although the type of selective serotonin reuptake inhibitor used concurrently with rivaroxaban was not found to influence the patients' bleeding risk, a significant increase in the risk of bleeding was bserved based on the dose of rivaroxaban used.
- |||||||||| escitalopram / Generic mfg.
Journal: Serotonin Surge: Intravenous Escitalopram as a Rare Cause of Drug-Induced Aplastic Anaemia. (Pubmed Central) - Apr 12, 2022
In addition, hyperbaric oxygen comprehensive therapy can promote the recovery of neurological function in patients with poststroke depression and significantly improve the depressive state and sleep quality of patients. Escitalopram is an uncommon medication that could lead to drug-induced aplastic anaemia.The adverse effects of escitalopram on red cell, white cell and platelet counts may be exacerbated on intravenous administration of the medication.Timely diagnosis is vital for the effective treatment of severe aplastic anaemia, avoiding complications and preventing recurrence.
- |||||||||| escitalopram / Generic mfg.
Trial initiation date: Escitalopram to Placebo in Patients With Localized Pancreatic Cancer (clinicaltrials.gov) - Apr 10, 2022
P2, N=46, Not yet recruiting,
Escitalopram is an uncommon medication that could lead to drug-induced aplastic anaemia.The adverse effects of escitalopram on red cell, white cell and platelet counts may be exacerbated on intravenous administration of the medication.Timely diagnosis is vital for the effective treatment of severe aplastic anaemia, avoiding complications and preventing recurrence. Initiation date: Mar 2022 --> Jun 2022
- |||||||||| escitalopram / Generic mfg.
Retrospective data, Review, Journal: Efficacy of escitalopram for poststroke depression: a systematic review and meta-analysis. (Pubmed Central) - Apr 9, 2022
The study suggests that escitalopram has a potentially effective role compared with control groups and demonstrates escitalopram is safe. However, the results of the motor function and the incidence of drowsiness should be considered carefully and remain to be discussed in the future.
|
